Global Orphan Drugs Market Outlook 2020
Orphan drugs, also called niche busters, are intended to treat patients suffering from very serious diseases for which no treatment or at least a satisfactory one, has so far been available. These diseases, often referred to as orphan diseases or rare diseases, affect only a small portion of the population. The number of diseases for which no treatment is currently available is estimated to be between 4,000 to 5,000, worldwide. The patent expiry of blockbuster drugs and increased competition from generics has shifted the focus of pharmaceutical industry from the essential medicines to orphan drugs. Incentives for drug development provided by governments, as well as support from the regulatory bodies, are a further boost for the companies developing orphan drugs all over the world.
According to the report “Global Orphan Drugs Market Outlook 2020”, the orphan drug market is anticipated to reach around US$ 180 Billion by 2020. The report provides a detailed analysis of the market for these orphan drugs. An estimation of the market potential of these drugs has been done keeping in mind that many more of these drugs are being tested in clinical trials for various indications, apart from the ones that are already approved. Furthermore, the report also provides the revenue generated by top 10 orphan drugs in 2014.
The report provides information about the segments of the orphan drug market on the basis of type, geography, and therapeutic application. It also highlights orphan drugs at various stages of clinical development. In addition, the report also provides insight about the major drivers and challenges, latest trends and developments, and strategic collaborations impacting the industry growth. The regulatory scenario of orphan drug industry across different geographic regions of the world has also been discussed in the report.
The later part of the report discusses some of the prominent players in the global orphan drug market. A brief business overview of each player has been provided along with their business segments, product portfolios, and recent developments. Moreover, analysis of their strengths and weaknesses has also been done. Overall, the report will prove as a complete source of knowledge and analysis for clients and potential investors.
According to the report “Global Orphan Drugs Market Outlook 2020”, the orphan drug market is anticipated to reach around US$ 180 Billion by 2020. The report provides a detailed analysis of the market for these orphan drugs. An estimation of the market potential of these drugs has been done keeping in mind that many more of these drugs are being tested in clinical trials for various indications, apart from the ones that are already approved. Furthermore, the report also provides the revenue generated by top 10 orphan drugs in 2014.
The report provides information about the segments of the orphan drug market on the basis of type, geography, and therapeutic application. It also highlights orphan drugs at various stages of clinical development. In addition, the report also provides insight about the major drivers and challenges, latest trends and developments, and strategic collaborations impacting the industry growth. The regulatory scenario of orphan drug industry across different geographic regions of the world has also been discussed in the report.
The later part of the report discusses some of the prominent players in the global orphan drug market. A brief business overview of each player has been provided along with their business segments, product portfolios, and recent developments. Moreover, analysis of their strengths and weaknesses has also been done. Overall, the report will prove as a complete source of knowledge and analysis for clients and potential investors.
1. ANALYST VIEW
2. RESEARCH METHODOLOGY
3. ORPHAN DRUG – AN INTRODUCTION
4. DRIVERS AND CHALLENGES
4.1 Drivers
4.1.1 Rising Healthcare Expenditure
4.1.2 Increasing Prevalence of Chronic Diseases
4.1.3 Shorter Development Timeline & Orphan Drug Exclusivity (ODE)
4.1.4 Grants and Tax Credits
4.2 Challenges
4.2.1 High Cost of Orphan Drugs
4.2.2 Lack of Disease History Awareness & Research Participants
4.2.3 Increased Competition from Generics Industry
5. GLOBAL ORPHAN DRUG MARKET - OVERVIEW
6. MARKET SEGMENTATION
6.1 By Type
6.2 By Geography
6.3 By Applications
7. CURRENT STATUS OF ORPHAN DRUGS IN PIPELINE
8. TRENDS AND DEVELOPMENTS
8.1 Rise in Number of Orphan Drugs for Oncology
8.2 Gene Therapy- Gaining Popularity for Rare Conditions
9. MERGERS AND ACQUISITIONS
10. REGULATORY SCENARIO
10.1 US
10.2 EU
10.3 Japan
10.4 India
10.5 China
11. COMPETITIVE LANDSCAPE
12. KEY PLAYER ANALYSIS
12.1 Novartis
12.2 F. Hoffmann-La Roche AG
12.3 Celgene Corporation
12.4 Pfizer Inc.
12.5 Sanofi
12.6 Bristol-Myers Squibb
12.7 Johnson & Johnson
12.8 Merck & Co., Inc.
12.9 Boehringer Ingelheim GmbH
12.10 AbbVie
13. OPPORTUNITIES & RECOMMENDATIONS
13.1 Opportunities
13.2 Recommendations
2. RESEARCH METHODOLOGY
3. ORPHAN DRUG – AN INTRODUCTION
4. DRIVERS AND CHALLENGES
4.1 Drivers
4.1.1 Rising Healthcare Expenditure
4.1.2 Increasing Prevalence of Chronic Diseases
4.1.3 Shorter Development Timeline & Orphan Drug Exclusivity (ODE)
4.1.4 Grants and Tax Credits
4.2 Challenges
4.2.1 High Cost of Orphan Drugs
4.2.2 Lack of Disease History Awareness & Research Participants
4.2.3 Increased Competition from Generics Industry
5. GLOBAL ORPHAN DRUG MARKET - OVERVIEW
6. MARKET SEGMENTATION
6.1 By Type
6.2 By Geography
6.3 By Applications
7. CURRENT STATUS OF ORPHAN DRUGS IN PIPELINE
8. TRENDS AND DEVELOPMENTS
8.1 Rise in Number of Orphan Drugs for Oncology
8.2 Gene Therapy- Gaining Popularity for Rare Conditions
9. MERGERS AND ACQUISITIONS
10. REGULATORY SCENARIO
10.1 US
10.2 EU
10.3 Japan
10.4 India
10.5 China
11. COMPETITIVE LANDSCAPE
12. KEY PLAYER ANALYSIS
12.1 Novartis
12.2 F. Hoffmann-La Roche AG
12.3 Celgene Corporation
12.4 Pfizer Inc.
12.5 Sanofi
12.6 Bristol-Myers Squibb
12.7 Johnson & Johnson
12.8 Merck & Co., Inc.
12.9 Boehringer Ingelheim GmbH
12.10 AbbVie
13. OPPORTUNITIES & RECOMMENDATIONS
13.1 Opportunities
13.2 Recommendations
LIST OF FIGURES:
Figure 5-1: Global - Orphan Drugs Market (Billion US$), 2014-2020
Figure 6-1: Global - Orphan Drugs Market by Type (%), 2014
Figure 6-2: Global - Orphan Drugs Market by Geography (%), 2014
Figure 6-3: Global - Orphan Drugs Market by Applications (%), 2014
Figure 11-1: Share of Major Players in Orphan Drugs Market (%), 2014
Figure 12-1: Novartis - Breakup of Revenue by Geographies (%), 2014
Figure 12-2: Roche - Breakup of Revenue by Geographies (%), 2014
Figure 12-3: Celgene Corporation - Breakup of Revenue by Geographies (%), 2014
Figure 12-4: Pfizer Inc - Breakup of Revenue by Geographies (%), 2014
Figure 12-5: Sanofi – Breakup of Revenue by Geographies (%), 2014
Figure 12-6: Bristol Myers Squibb – Breakup of Revenue by Geographies (%), 2014
Figure 12-7: Johnson & Johnson - Breakup of Revenue by Geographies (%), 2014
Figure 12-8: Merck & Co., Inc. - Breakup of Revenue by Geographies (%), 2014
Figure 12-9: Boehringer Ingelheim GmbH - Break up of Revenue by Geographies (%), 2014
Figure 12-10: AbbVie - Break up of Revenue by Geographies (%), 2014
Figure 5-1: Global - Orphan Drugs Market (Billion US$), 2014-2020
Figure 6-1: Global - Orphan Drugs Market by Type (%), 2014
Figure 6-2: Global - Orphan Drugs Market by Geography (%), 2014
Figure 6-3: Global - Orphan Drugs Market by Applications (%), 2014
Figure 11-1: Share of Major Players in Orphan Drugs Market (%), 2014
Figure 12-1: Novartis - Breakup of Revenue by Geographies (%), 2014
Figure 12-2: Roche - Breakup of Revenue by Geographies (%), 2014
Figure 12-3: Celgene Corporation - Breakup of Revenue by Geographies (%), 2014
Figure 12-4: Pfizer Inc - Breakup of Revenue by Geographies (%), 2014
Figure 12-5: Sanofi – Breakup of Revenue by Geographies (%), 2014
Figure 12-6: Bristol Myers Squibb – Breakup of Revenue by Geographies (%), 2014
Figure 12-7: Johnson & Johnson - Breakup of Revenue by Geographies (%), 2014
Figure 12-8: Merck & Co., Inc. - Breakup of Revenue by Geographies (%), 2014
Figure 12-9: Boehringer Ingelheim GmbH - Break up of Revenue by Geographies (%), 2014
Figure 12-10: AbbVie - Break up of Revenue by Geographies (%), 2014
LIST OF TABLES:
Table 7-1: Major Orphan Drugs Pipeline
Table 9-1: Major Consolidations in Orphan Drug Market (2014-2015)
Table 11-1: Global - Major Orphan Drugs Revenue (Billion US$), 2014
Table 12-1: Novartis - Revenue by Business Segments (Billion US$), 2013 & 2014
Table 12-2: Novartis - Orphan Drugs
Table 12-3: Roche - Revenue by Business Segments (Billion US$), 2013 & 2014
Table 12-4: Roche - Orphan Drugs
Table 12-5: Celgene Corporation - Orphan Drugs
Table 12-6: Pfizer Inc - Revenues by Business Segment (Billion US$), 2013 & 2014
Table 12-7: Pfizer Inc - Orphan Drugs
Table 12-8: Sanofi - Revenue by Business Segments (Billion US$), 2013 & 2014
Table 12-9: Sanofi - Orphan Drugs
Table 12-10: Bristol Myers Squibb - Revenue by Business Segments (Billion US$), 2013 & 2014
Table 12-11: Bristol Myers Squibb - Orphan Drugs
Table 12-12: Johnson & Johnson - Revenue by Business Segments (Billion US$), 2013 & 2014
Table 12-13: Johnson & Johnson - Orphan Drugs
Table 12-14: Merck & Co., Inc. - Revenue by Business Segments (Billion US$), 2013 & 2014
Table 12-15: Merck & Co., Inc. - Orphan Drugs
Table 12-16: Boehringer Ingelheim GmbH - Revenues by Business Segment (Billion US$), 2013 & 2014
Table 12-17: Boehringer Ingelheim GmbH - Orphan Drugs
Table 12-18: AbbVie - Orphan Drugs
Table 7-1: Major Orphan Drugs Pipeline
Table 9-1: Major Consolidations in Orphan Drug Market (2014-2015)
Table 11-1: Global - Major Orphan Drugs Revenue (Billion US$), 2014
Table 12-1: Novartis - Revenue by Business Segments (Billion US$), 2013 & 2014
Table 12-2: Novartis - Orphan Drugs
Table 12-3: Roche - Revenue by Business Segments (Billion US$), 2013 & 2014
Table 12-4: Roche - Orphan Drugs
Table 12-5: Celgene Corporation - Orphan Drugs
Table 12-6: Pfizer Inc - Revenues by Business Segment (Billion US$), 2013 & 2014
Table 12-7: Pfizer Inc - Orphan Drugs
Table 12-8: Sanofi - Revenue by Business Segments (Billion US$), 2013 & 2014
Table 12-9: Sanofi - Orphan Drugs
Table 12-10: Bristol Myers Squibb - Revenue by Business Segments (Billion US$), 2013 & 2014
Table 12-11: Bristol Myers Squibb - Orphan Drugs
Table 12-12: Johnson & Johnson - Revenue by Business Segments (Billion US$), 2013 & 2014
Table 12-13: Johnson & Johnson - Orphan Drugs
Table 12-14: Merck & Co., Inc. - Revenue by Business Segments (Billion US$), 2013 & 2014
Table 12-15: Merck & Co., Inc. - Orphan Drugs
Table 12-16: Boehringer Ingelheim GmbH - Revenues by Business Segment (Billion US$), 2013 & 2014
Table 12-17: Boehringer Ingelheim GmbH - Orphan Drugs
Table 12-18: AbbVie - Orphan Drugs
